Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.

The lower benefit in the olmesartan arm of KARDIA-2 could draw scrutiny, but the company said it was expected and noted polypharmacy is common in hypertension.

Seven novel agents approved in March include one accelerated approval, two rare pediatric disease priority review vouchers, two breakthrough therapy designations and one regenerative medicine advance therapy designation.

The family-owned German firm's legacy lies in the cardiometabolic space but it has been building a pipeline across a range of neuropsychiatric diseases. The collaboration with Sosei Heptares, which has been sealed with a upfront payment of €25m, will focus on schizophrenia.